Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avangrid, Inc. stock logo
AGR
Avangrid
$36.55
-1.3%
$34.80
$27.46
$41.22
$14.14B0.56922,440 shs588,628 shs
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$0.08
$0.12
$0.07
$1.42
$2.80M1.973.36 million shs528,287 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avangrid, Inc. stock logo
AGR
Avangrid
-1.27%+0.83%+2.52%+20.03%-7.59%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
+0.52%-7.50%-43.61%-52.62%+7,769,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avangrid, Inc. stock logo
AGR
Avangrid
3.567 of 5 stars
0.92.02.52.72.41.73.1
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avangrid, Inc. stock logo
AGR
Avangrid
1.75
Reduce$34.75-4.92% Downside
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Latest E25, RWD, AGR, NBY, and ORCP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/8/2024
Avangrid, Inc. stock logo
AGR
Avangrid
Janney Montgomery Scott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Sell$35.00
2/23/2024
Avangrid, Inc. stock logo
AGR
Avangrid
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$34.00 ➝ $35.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avangrid, Inc. stock logo
AGR
Avangrid
$8.31B1.70$5.05 per share7.24$53.46 per share0.68
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$14.73M0.19N/AN/A$0.12 per share0.65

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avangrid, Inc. stock logo
AGR
Avangrid
$786M$2.3115.8215.102.7510.80%4.37%2.10%7/24/2024 (Estimated)
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$3.82N/A1.11N/A-65.46%-150.14%-53.48%5/28/2024 (Estimated)

Latest E25, RWD, AGR, NBY, and ORCP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2024Q1 2024
Avangrid, Inc. stock logo
AGR
Avangrid
$0.70$0.88+$0.18$0.85$2.54 billion$2.42 billion    
3/26/2024Q4 2023
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A-$0.95-$0.95-$0.57N/A$3.73 million    
2/22/2024Q4 2023
Avangrid, Inc. stock logo
AGR
Avangrid
$0.94$0.97+$0.03$0.91$2.40 billion$2.28 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avangrid, Inc. stock logo
AGR
Avangrid
$1.764.82%N/A76.19%N/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A

Latest E25, RWD, AGR, NBY, and ORCP Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/11/2024
Avangrid, Inc. stock logo
AGR
Avangrid
quarterly$0.444.9%5/31/20246/3/20247/1/2024
2/15/2024
Avangrid, Inc. stock logo
AGR
Avangrid
quarterly$0.445.6%2/29/20243/1/20244/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avangrid, Inc. stock logo
AGR
Avangrid
0.48
0.65
0.56
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.67
1.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avangrid, Inc. stock logo
AGR
Avangrid
13.12%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
23.25%

Insider Ownership

CompanyInsider Ownership
Avangrid, Inc. stock logo
AGR
Avangrid
0.06%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
1.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avangrid, Inc. stock logo
AGR
Avangrid
7,999386.78 million386.55 millionOptionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
2436.06 million35.59 millionNot Optionable

E25, RWD, AGR, NBY, and ORCP Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Avangrid logo

Avangrid

NYSE:AGR
Avangrid, Inc., an energy services holding company, engages in the regulated energy transmission and distribution, and renewable energy generation businesses in the United States. The company operates through Networks and Renewables segments. It is involved in the generation, transmission, and distribution of electricity; and distribution, transportation, and sale of natural gas. In addition, the company operates renewable energy generation facilities primarily using onshore wind power, as well as solar, biomass, and thermal power. Further, it delivers natural gas and electricity to residential, commercial, and institutional customers through its regulated utilities in New York, Maine, Connecticut, and Massachusetts; and sells its output to investor-owned utilities, public utilities, and other credit-worthy entities, as well as generates and provides power and other services to federal and state agencies, institutional retail, and joint action agencies. Additionally, the company delivers thermal output to wholesale customers in the Western United States. It owns eight electric and natural gas utilities, serving 3.3 million customers in New York and New England, as well as owns and operates 9.3 gigawatts of electricity capacity primarily through wind power in 22 states. Avangrid, Inc. was incorporated in 1997 and is headquartered in Orange, Connecticut. The company operates as a subsidiary of Iberdrola, S.A.
NovaBay Pharmaceuticals logo

NovaBay Pharmaceuticals

NYSE:NBY
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.